Investors

Investors

Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

NASDAQ: TTPH
$ 4.07 -0.11 (2.63%)
Day High: 4.23
Day Low:  4.06
Volume:    179,010
4:00 PM ET
Jan 20, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Nov 15, 2016 / 3:00 PM ET
Aug 24, 2016 / 3:30 PM CT